Robert Anders

17PUBLICATIONS
222CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumoursPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

|Jan 12, 2026
A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.

Katherine M Bever, Amanda L Huff, Ludmila Danilova

|Aug 15, 2025
Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment.

Dimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel

|May 23, 2025
A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma.

Parul Agarwal, Matthew Guo, Kabeer Munjal

|May 19, 2025
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Eric S Christenson, Won Jin Ho, Daniel Shu

|Nov 21, 2024
Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy.

Tracee L McMiller, Sepideh Besharati, Mark Yarchoan

Pageof 3

Frequent Collaborators

9 joint publications

Elizabeth M Jaffee

8 joint publications

Qingfeng Zhu

7 joint publications

Won Jin Ho

6 joint publications

Mark Yarchoan